KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Amortization - Deferred Charges (2020 - 2022)

TherapeuticsMD's Amortization - Deferred Charges history spans 3 years, with the latest figure at $2.6 million for Q3 2022.

  • For Q3 2022, Amortization - Deferred Charges rose 74.81% year-over-year to $2.6 million; the TTM value through Sep 2022 reached $21.1 million, up 317.92%, while the annual FY2021 figure was $5.7 million, 124.68% up from the prior year.
  • Amortization - Deferred Charges reached $2.6 million in Q3 2022 per TXMD's latest filing, down from $7.9 million in the prior quarter.
  • In the past five years, Amortization - Deferred Charges ranged from a high of $9.0 million in Q1 2022 to a low of $372000.0 in Q2 2020.
  • Average Amortization - Deferred Charges over 3 years is $2.7 million, with a median of $1.4 million recorded in 2021.
  • Peak YoY movement for Amortization - Deferred Charges: surged 54.98% in 2021, then skyrocketed 611.32% in 2022.
  • A 3-year view of Amortization - Deferred Charges shows it stood at $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then skyrocketed by 68.65% to $2.6 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Amortization - Deferred Charges are $2.6 million (Q3 2022), $7.9 million (Q2 2022), and $9.0 million (Q1 2022).